Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide is an experimental small molecule compound belonging to the class of n-benzylpiperidines. It has not been approved for any therapeutic use and is not currently in clinical development beyond preclinical or early research stages. The compound has been studied as a potential inhibitor of beta-site APP-cleaving enzyme 1 (BACE1), an aspartic protease involved in the production of beta-amyloid peptides implicated in Alzheimer's disease pathology. By inhibiting BACE1, this molecule may reduce amyloid-beta formation and could have potential applications in neurodegenerative diseases such as Alzheimer's disease[6][2]. However, there are no reported clinical trials or approved indications for this drug.
- Other names
- DB07735DB-07735DB 07735
02
Targets
BACE1 (Beta-site APP-cleaving enzyme 1)
Beyond the preview
Go deeper on N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide.